Translation in solid cancer: are size‐based response criteria an anachronism? M. FernandesD. RoselJ. Brábek Educational Series – Blue Series 30 July 2014 Pages: 1 - 10
Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology J. de CastroM. CoboJ. Ferreirós Educational Series – Red Series 06 November 2014 Pages: 11 - 23
Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain G. VillaL. J. Hernández-PastorM. Cuesta Research Article 01 July 2014 Pages: 24 - 33
MiR-215/192 participates in gastric cancer progression Y. J. XuY. Fan Brief Research Article 01 July 2014 Pages: 34 - 40
EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma Z. Q. XuL. ZhangY. W. Fu Research Article 02 July 2014 Pages: 41 - 49
Interleukin-17 is a favorable prognostic marker for colorectal cancer Y. LinJ. XuK. Huang Research Article 12 July 2014 Pages: 50 - 56
Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy L.-P. GeJ. LiL.-R. Zhu Research Article 05 July 2014 Pages: 57 - 64
Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53 Z.-G. ShiS.-Q. LiG. Liu Research Article 16 July 2014 Pages: 65 - 73
A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products A. Estévez-BraunA. G. RaveloJ. C. Lacal Research Article 04 December 2014 Pages: 74 - 84
Indirect comparisons in cost-effectiveness analysis: are we being naïve? J. Martin-Broto Correspondence 21 November 2014 Pages: 85 - 86
